Vos Lukas M, Stegenga Boudewijn, Stant A Dennis, Quik Elize H, Huddleston Slater James Jr
J Oral Facial Pain Headache. 2018 Spring;32(2):198–207. doi: 10.11607/ofph.1457. Epub 2018 Feb 21.
To determine the cost effectiveness and cost utility of arthrocentesis as an initial treatment for temporomandibular joint (TMJ) arthralgia compared to usual care.
A two-armed, parallel-design, randomized controlled trial (RCT) was conducted in the Netherlands from January 2009 to June 2012 that included patients with TMJ arthralgia. Patients were randomly allocated to arthrocentesis (n = 40) or usual care (n = 40) for initial treatment. Arthrocentesis consisted of rinsing the intra-articular space with isotonic saline, and usual care included a soft diet, physical therapy, and splint therapy. The duration of the usual care program was 6 weeks, and follow-up was conducted 3, 12, and 26 weeks after its completion. Generalized estimated equation multivariate models were assessed in order to correct for the dependency of repeated measurements in the longitudinal data analysis. An independent samples t test was used to compare the arthrocentesis group with the usual care group for TMJ pain after 26 weeks. Cost effectiveness (total cost from a societal view) was related to TMJ pain (as measured on a visual analog scale [0 to 100 mm]) and to cost utility (quality-adjusted life years).
TMJ pain declined more quickly in the arthrocentesis group (n = 36) than in the usual care group (n = 36) (regression coefficient β = -10.76; 95% confidence interval [CI] = -17.75 to -3.77; P = .003). The estimated mean total (ie, societal) cost over 26 weeks was €589 (US $795) in the arthrocentesis group and €1,680 (US $2,266) in the usual care group. Arthrocentesis was associated with a lower mean cost and better health outcomes than usual care in 98% and 95% of the bootstrap simulations, respectively.
The results of this study suggest that, from an economical perspective, arthrocentesis may be superior to usual care for the initial treatment of TMJ pain, as it had better health outcomes and lower costs than usual care.
与常规治疗相比,确定关节穿刺术作为颞下颌关节(TMJ)关节痛初始治疗方法的成本效益和成本效用。
2009年1月至2012年6月在荷兰进行了一项双臂、平行设计的随机对照试验(RCT),纳入了TMJ关节痛患者。患者被随机分配接受关节穿刺术(n = 40)或常规治疗(n = 40)作为初始治疗。关节穿刺术包括用等渗盐水冲洗关节腔,常规治疗包括软食、物理治疗和夹板治疗。常规治疗方案持续6周,在其结束后3周、12周和26周进行随访。为校正纵向数据分析中重复测量的依赖性,评估了广义估计方程多变量模型。使用独立样本t检验比较关节穿刺术组和常规治疗组在26周后的TMJ疼痛情况。成本效益(从社会角度的总成本)与TMJ疼痛(以视觉模拟量表[0至100毫米]测量)和成本效用(质量调整生命年)相关。
关节穿刺术组(n = 36)的TMJ疼痛下降速度比常规治疗组(n = 36)更快(回归系数β = -10.76;95%置信区间[CI] = -17.75至-3.77;P = .003)。关节穿刺术组26周的估计平均总(即社会)成本为589欧元(795美元),常规治疗组为1680欧元(2266美元)。在98%的自抽样模拟中,关节穿刺术与比常规治疗更低的平均成本相关,在95%的自抽样模拟中,与更好的健康结果相关。
本研究结果表明,从经济角度来看,关节穿刺术作为TMJ疼痛的初始治疗方法可能优于常规治疗,因为它比常规治疗具有更好的健康结果和更低的成本。